NeoGenomics - NEO Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 4 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.

12 brokerages have issued 12 month target prices for NeoGenomics' stock. Their NEO share price forecasts range from $15.00 to $28.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 11.4% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.

NeoGenomics' stock was trading at $9.24 at the start of the year. Since then, NEO stock has increased by 87.9% and is now trading at $17.36.
View the best growth stocks for 2023 here.

NeoGenomics saw a increase in short interest in March. As of March 15th, there was short interest totaling 6,490,000 shares, an increase of 26.5% from the February 28th total of 5,130,000 shares. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is currently 6.1 days.
View NeoGenomics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 26th 2023.
View our NEO earnings forecast.

NeoGenomics, Inc. (NASDAQ:NEO) issued its earnings results on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to analysts' expectations of $125.09 million. NeoGenomics had a negative trailing twelve-month return on equity of 9.15% and a negative net margin of 28.30%. The firm's revenue for the quarter was down 3.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.04 EPS.

ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), SPDR S&P Health Care Services ETF (XHS), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Principal Healthcare Innovators ETF (BTEC), SPDR S&P 600 Small CapValue ETF (SLYV), iShares S&P Small-Cap 600 Value ETF (IJS) and iShares U.S. Healthcare Providers ETF (IHF).

NeoGenomics issued an update on its FY 2023 earnings guidance on Thursday, February, 23rd. The company provided earnings per share guidance of -$0.38--$0.32 for the period, compared to the consensus earnings per share estimate of -$0.53. The company issued revenue guidance of $545.00 million-$555.00 million, compared to the consensus revenue estimate of $535.08 million.

116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Brown Advisory Inc. (5.07%), T. Rowe Price Investment Management Inc. (2.31%), First Light Asset Management LLC (2.12%), Millennium Management LLC (2.10%), Geode Capital Management LLC (1.91%) and Schroder Investment Management Group (1.82%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.

Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NEO stock can currently be purchased for approximately $17.36.

NeoGenomics (NASDAQ:NEO) has a market capitalization of $2.21 billion and generates $509.73 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

The company employs 2,100 workers across the globe.

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.